

**NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)** 

# Waldenström Macroglobulinemia/

# Lymphoplasmacytic Lymphoma

Version 1.2025 — September 13, 2024

NCCN.org

NCCN recognizes the importance of clinical trials and encourages participation when applicable and available. Trials should be designed to maximize inclusiveness and broad representative enrollment.

NCCN Guidelines for Patients<sup>®</sup> available at <u>www.nccn.org/patients</u>

Continue

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

NCCN Guidelines Index Table of Contents Discussion

\*Shaji K. Kumar, MD/Chair ‡ Mayo Clinic Comprehensive Cancer Center

\*Natalie S. Callander, MD/Vice Chair ‡ ξ University of Wisconsin Carbone Cancer Center

Kehinde Adekola, MD, MSCI ‡ Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Larry D. Anderson, Jr., MD, PhD ‡ UT Southwestern Simmons Comprehensive Cancer Center

\***Muhamed Baljevic, MD ‡ Þ** ξ Vanderbilt-Ingram Cancer Center

Rachid Baz, MD ‡ Moffitt Cancer Center

Erica Campagnaro, MD ‡ University of Michigan Rogel Cancer Center

**Caitlin Costello, MD ‡ Þ ξ** UC San Diego Moores Cancer Center

**Christopher D'Angelo, MD ‡** Fred & Pamela Buffett Cancer Center

Benjamin Derman, MD † ‡ The UChicago Medicine Comprehensive Cancer Center

Srinivas Devarakonda, MD ‡ The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute **Noura Elsedawy, MD †** St. Jude Children's Research Hospital/ The University of Tennessee Health Science Center

Amandeep Godara, MD ‡ Huntsman Cancer Institute at the University of Utah

Kelly Godby, MD ‡ O'Neal Comprehensive Cancer Center at UAB

Jens Hillengass, MD, PhD ‡ Roswell Park Comprehensive Cancer Center

**Leona Holmberg, MD, PhD ‡ ξ** Fred Hutchinson Cancer Center

Myo Htut, MD **‡** Þ City of Hope National Medical Center

**Carol Ann Huff, MD † ‡** Johns Hopkins Kimmel Cancer Center

Malin Hultcrantz, MD, PhD ‡ Memorial Sloan Kettering Cancer Center

Yubin Kang, MD  $\ddagger \dagger \xi$ Duke Cancer Institute

Sarah Larson, MD † ‡ UCLA Jonsson Comprehensive Cancer Center

Hans C. Lee, MD ‡ ‡ The University of Texas MD Anderson Cancer Center

Michaela Liedtke, MD ‡ Stanford Cancer Institute Thomas Martin, MD ‡ UCSF Helen Diller Family Comprehensive Cancer Center

James Omel, MD ¥ Patient Advocate

Timothy Robinson, MD, PhD § Yale Cancer Center/Smilow Cancer Hospital

**Aaron Rosenberg**, **MD ‡** ξ UC Davis Comprehensive Cancer Center

Mark A. Schroeder, MD ‡ Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Daniel Sherbenou, MD, PhD † University of Colorado Cancer Center

Attaya Suvannasankha, MD ‡ Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Jason Valent, MD ‡ Case Comprehensive Cancer Center/ University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Asya Nina Varshavsky-Yanovsky, MD, PhD † ‡ Fox Chase Cancer Center

**Dan Vogl, MD ‡** Abramson Cancer Center at the University of Pennsylvania

<u>NCCN</u> Emily Kovach Rashmi Kumar, PhD

 ξ Bone marrow transplantation + Hematology/Hematology oncology

 Patient advocacy § Radiation oncology
 \* Discussion section writing committee

NCCN Guidelines Panel Disclosures



NCCN National Comprehensive Cancer Network® NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

NCCN Guidelines Index Table of Contents Discussion

NCCN Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Panel Members Summary of Guidelines Updates

Diagnosis and Workup (WM/LPL-1) Asymptomatic or Minimally Symptomatic (WM/LPL-2) Primary Treatment, Response, Relapse (WM/LPL-3)

WHO Criteria for Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia Waldenström Macroglobulinemia International Workshop Criteria (WM/LPL-A) Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Therapy (WM/LPL-B) Response Criteria for WM/LPL (WM/LPL-C) Management of Bing Neel Syndrome (BNS-1)

Abbreviations (ABBR-1)

Find an NCCN Member Institution: <u>https://www.nccn.org/home/member-institutions</u>.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See <u>NCCN Categories of Evidence</u> and Consensus.

NCCN Categories of Preference: All recommendations are considered

See <u>NCCN Categories of</u> <u>Preference</u>.

appropriate.

The NCCN Guidelines<sup>®</sup> are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network<sup>®</sup> (NCCN<sup>®</sup>) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network<sup>®</sup>. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2024.

Version 1.2025 09/13/2024 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

NCCN NCCN Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

Updates in Version 1.2025 of the NCCN Guidelines for WM/LPL from Version 2.2024 include:

Global

· References updated throughout Guidelines.

WM/LPL-1

• Workup, essential, bullet 9 modified: Chest/abdomen/pelvis CT ± contrast and/or FDG-PET/CT when possible.

WM/LPL-3

- Primary treatment and relapse links to NCCN Guidelines for B-Cell Lymphoma modified: Follicular Lymphoma Histologic Transformation of Indolent Lymphoma to DLBCL.
- If treated with BTK inhibitor regimens algorithm modified: Continue treatment until disease progression symptomatic disease progression (beyond biochemical progression) or unacceptable toxicity.
- Footnote r added: In patients with neuropathy, symptom stability might be the goal of therapy as neuropathy symptoms take time to improve.

#### WM/LPL-B (1 of 4)


- General principles, bullet 2, if candidates for hematopoietic cell transplantation (HCT), sub-bullet modified: Exposure to nucleoside analogs (fludarabine and cladribine) should be avoided in patients who may be potential autologous HCT candidates.
- Plasmapheresis recommendation updated: ofatumumab removed.
- Screening recommendations updated:
- Bullet removed: Test for hepatitis B before starting carfilzomib, rituximab, or ofatumumab.
- Bullet updated: Screen for HIV, *hepatitis B*, and hepatitis C as clinically indicated.
- Dosing and administration of proteasome inhibitors, bullet 3 updated: Carfilzomib may be used once (preferred) or twice weekly at different doses.

#### <u>WM/LPL-B (2 of 4)</u>

- Regimens updated:
- Bortezomib/dexamethasone/rituximab moved from preferred to other recommended regimens.
- Rituximab/cyclophosphamide/dexamethasone ± *bortezomib*.
- Footnote removed: Consider for patients presenting with symptomatic hyperviscosity, or in whom rapid IgM reduction is required. (Also WM/LPL-B [3 of 4]).

### <u>WM/LPL-B (3 of 4)</u>

- Regimens updated:
- Bortezomib/dexamethasone/rituximab moved from preferred to other recommended regimens.
- Bendamustine and rituximab moved from other recommended regimens to useful in certain circumstances.
- Pirtobrutinib added to useful in certain circumstances.
- Ofatumumab (for rituximab-intolerant individuals) removed from useful in certain circumstances.
- Footnote removed: Consider for patients presenting with symptomatic hyerviscosity, or in whom rapid IgM reduction is required.
- Footnote removed: Ofatumumab may be used for rituximab-intolerant individuals as a single agent or in combination therapy anywhere that rituximab is given. While ofatumumab is no longer commercially available, it may be obtained for clinical use.




<sup>a</sup> Frailty assessment should be considered in older adults. See <u>NCCN Guidelines for Older</u>

#### Adult Oncology

- WHO Criteria for Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia (WM/LPL-A).
- <sup>c</sup> Lymphoplasmacytic lymphoma (LPL) encompasses IgG, IgA, serum free light chain alone, and non-secretory subtypes, although makes up <5% of all LPLs. The treatment of non-IgM LPLs parallels that of IgM-secreting LPLs, but these are less likely to have either hyperviscosity associated with them, or autoimmune-related neuropathy. It is important to differentiate from IgM MGUS or IgM multiple myeloma.
- differentiate from IgM MGUS or IgM multiple myeloma.
   d MYD88 wild-type occurs in <10% of patients and should not be used to exclude diagnosis of WM if other criteria are met.</li>

- <sup>e</sup> Studies have shown that mutations in this gene are found in up to 40% of patients with Waldenström macroglobulinemia (WM)/LPL and can impact ibrutinib response.
   <sup>f</sup> Consider in patients with suspected cryoglobulinemia.
- <sup>9</sup> If cryocrit is positive, then repeat testing of initial serum IgM, and obtain all subsequent serum IgM levels under warm conditions.
- <sup>h</sup> In patients presenting with suspected disease related to peripheral neuropathy, rule out amyloidosis in patients presenting with nephrotic syndrome or unexplained cardiac . problems.
- <sup>i</sup> Confirm symptoms are not related to or caused by comorbidities.



Reserve therapy only for symptomatic patients, as untreated asymptomatic patients have similar survival than age- and sex-matched individuals of the general population.

<sup>k</sup> Risk score calculator available at <u>www.awmrisk.com</u>. All values taken at approximately the same time.

Confirm symptoms are not related to or caused by other comorbidities.

<sup>m</sup> Retinal examination once a year if serum IgM level >3000 mg/dL. Consider therapy in asymptomatic patients with serum IgM level >6000 mg/dL.

<sup>n</sup> Detection of cold agglutinins or cryoglobulins in the absence of symptoms does not represent a criterion to treat.

Note: All recommendations are category 2A unless otherwise indicated.

Version 1.2025 09/13/2024 © 2024 National Comprehensive Cancer Network® (NCCN®), All rights reserved. NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN.

Natio	nal orehei er	NCCN Guideline	s Version 1.2025 acroglobulinemia/ cytic Lymphoma	NCCN Guidelines Index Table of Contents Discussion
PRIMARY TREATMENT <sup>o</sup>		MANAGEMENT AFTER PRIMARY TREATMENT		RELAPSE
Plasmapheresis for symptomatic hyperviscosity <sup>p</sup> and Primary therapy,		If treated with fixed-duration chemoimmunotherapy regimens	→ Observe <sup>s,t</sup> until progressive disease <sup>r,u</sup>	Consider previously used regimens, if well tolerated and had a prolonged response <sup>v</sup> see <u>WM/LPL-B</u>
see <u>WM/LPL-B</u> or Clinical trial If transformation see <u>NCCN</u> <u>Guidelines</u>	, 	If treated with BTK inhibitor regimens	<ul> <li>Continue treatment until symptomatic disease progression (beyond biochemical progression) or unacceptable toxicity</li> </ul>	Choose alternative therapy, see <u>WM/LPL-B<sup>v</sup></u> If transformation, see <u>NCCN</u>
for B-Cell Lymphomas, Histologic Transformation of Indolent Lymphoma to Diffuse Large B. coll Lymphoma		If persistent symptoms <sup>q</sup> No response/		Guidelines for B-Cell Lymphomas, Histologic Transformation of Indolent Lymphoma to DLBCL
B-cell Lymphoma (DLBCL)		No response/ Progressive disease <sup>r</sup>		

<sup>o</sup> Intent of therapy should be based on palliation of symptoms, not necessarily levels of IgM unless the patient is exhibiting evidence of symptomatic hyperviscosity.

<sup>p</sup> Plasmapheresis should be performed for patients with symptomatic hyperviscosity, and before treatment with rituximab-containing regimen in patients with IgM ≥4000 mg/dL. IgM should be monitored closely in these patients thereafter and plasmapheresis should be considered again if symptomatic hyperviscosity recurs or if IgM is ≥4000 mg/dL while on rituximab-containing therapy. Red blood cell (RBC) transfusion, if indicated, should be done after plasmapheresis to prevent added hyperviscosity load.

<sup>q</sup> In patients with neuropathy, symptom stability might be the goal of therapy as neuropathy symptoms take time to improve.

<sup>r</sup><u>Response Criteria for WM/LPL (WM/LPL-C)</u>.

<sup>s</sup> See <u>NCCN Guidelines for Survivorship</u>.

<sup>t</sup> CBC,CMP, and IgM every 3 months for 2 years, then every 4–6 months for additional 3 years, then every 6–12 months. Progression based on IgM levels alone, without symptoms, should not be reason to retreat.

- <sup>u</sup> Maintenance rituximab may be considered in select patients after chemoimmunotherapy regimens.
- <sup>v</sup> Caution should be used when re-treating with myelosuppressive regimens due to cumulative toxicities.

NCCN	National Comprehensive Cancer Network®
------	---

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

#### WHO CRITERIA FOR LYMPHOPLASMACYTIC LYMPHOMA AND WALDENSTRÖM MACROGLOBULINEMIA

- Lymphoplasmacytic lymphoma:
- → Neoplasm of small B lymphocytes, plasmacytoid lymphocytes, and plasma cells
- Usually involving bone marrow and sometimes lymph nodes and spleen
- > Does not fulfill criteria of any other small B-cell lymphoid neoplasm that may also have plasmacytic differentiation

Reproduced with permission from Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition. IARC, Lyon 2017.

#### Waldenström macroglobulinemia:

Lymphoplasmacytic lymphoma with bone marrow involvement and IgM monoclonal gammopathy of any concentration

Adapted with permission. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological Definition of Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-115.

- WALDENSTRÖM MACROGLOBULINEMIA INTERNATIONAL WORKSHOP CRITERIA
- Proposed Criteria for the Diagnosis of Waldenström Macroglobulinemia
- · IgM monoclonal gammopathy of any concentration
- Bone marrow infiltration by small lymphocytes, plasmacytoid cells, and plasma cells
- Diffuse, interstitial, or nodular pattern of bone marrow infiltration
- CD19+, CD20+, slgM+; CD5, CD10, CD23 can be expressed in some cases of Waldenström macroglobulinemia and does not exclude diagnosis.
- Reprinted with permission from Elsevier. Owen RG. Developing diagnostic criteria in Waldenström's macroglobulinemia. Semin Oncol 2003;30:196-200.

#### **REVISED IPSS WALDENSTRÖM MACROGLOBULINEMIA SCORING SYSTEM**

#### Criteria for the Diagnosis of Waldenström Macroglobulinemia (only at the time of initial treatment prognostication)

Table	1.
-------	----

	Points
Age <65	0
Age 66–75	1
Age >75	2
B2 microglobulin >4 mg/L	1
LDH >250 IU/L	1
Serum albumin <3.5 g/dL	1

Та	bl	е	2

Score*	Stage
0	Very Low
1	Low
2	Intermediate
3	High
4–5	Very High
*Sum of total points in Table 1	

Adapted with permission from: Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia 2019;33:2654-2661.

NCCN	National Comprehensive Cancer Network®
------	---

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

#### GENERAL CONSIDERATIONS FOR SYSTEMIC THERAPY FOR WM/LPL

#### **General Principles**

- Frailty assessment should be considered in older adults. See <u>NCCN Guidelines for Older Adult Oncology</u>.
- If candidates for hematopoietic cell transplantation (HCT)
- → Exposure to nucleoside analogs (fludarabine and cladribine) should be avoided.
- Plasmapheresis
- In patients with symptomatic hyperviscosity, plasmapheresis should first be performed; plasmapheresis should also be considered before treatment with rituximab for patients with asymptomatic WM with an IgM ≥4000 mg/dL or who are symptomatic to avoid aggravation of serum viscosity based on rituximab-related IgM flare. Rituximab may also be held in patients with elevated serum IgM levels for initial treatment cycles. Blood warmers should be used for apheresis if cryoprecipitate or cryoglobulin are present.

#### Screening Recommendations

• Screen for HIV, hepatitis B, and hepatitis C, as clinically indicated.

#### **Prophylaxis Recommendations**

- Pneumocystis jiroveci pneumonia (PJP) prophylaxis should be considered for patients receiving bendamustine/rituximab or fludarabine/ cyclophosphamide/rituximab.
- Administer herpes zoster prophylaxis for all patients treated with proteasome inhibitors and nucleoside analogs.
- Prophylactic antiviral therapy with entecavir is recommended for any patient who is hepatitis B surface antigen-positive and receiving anti-CD20 therapy. If there is active disease (PCR+), it is considered treatment/management and not prophylactic therapy. In cases of hepatitis B core antibody positivity, prophylactic antiviral therapy is preferred; however, if there is a concurrent high-level hepatitis B surface antibody, these patients may be monitored with serial hepatitis B viral load.

#### Side Effects and Laboratory Tests

- Carfilzomib can potentially cause cardiac and pulmonary toxicity, especially in older patients.
- Serial serum IgA and IgG levels should be carefully monitored as these can be depleted with WM therapies. See <u>Prevention and Treatment</u> of Cancer-Related Infections.
- Regimens containing bortezomib and vincristine are associated with higher risk of treatment-related peripheral neuropathy, especially in those with disease-related baseline neuropathy. Close monitoring or alternative therapies should be considered in some patients.

#### Dosing and Administration of Proteasome Inhibitors

- Subcutaneous bortezomib is the preferred method of administration.
- Both weekly and twice-weekly dosing schemas of bortezomib may be appropriate; weekly is preferred.
- Carfilzomib may be used once (preferred) or twice weekly and at different doses.

#### **Substitutions**

- Rituximab and hyaluronidase human injection for subcutaneous administration may be substituted for rituximab after patients have received the first full dose of rituximab by intravenous infusion.
- An U.S. Food and Drug Administration (FDA)-approved biosimilar is an appropriate substitute for rituximab.

Note: All recommendations are category 2A unless otherwise indicated.

NCCN National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

References

WM/LPL-B 2 OF 4

PRIMARY THERAPY FOR WM/LPL <sup>a</sup> (Order of regimens is alphabetical and does not indicate preference)		
<ul> <li><u>Preferred Regimens</u></li> <li>Bendamustine/rituximab</li> <li>Ibrutinib<sup>b</sup> ± rituximab (category 1)</li> <li>Zanubrutinib<sup>b</sup> (category 1)</li> </ul>		
Other Recommended Regimens • Bendamustine • Bortezomib/dexamethasone/rituximab • Carfilzomib/rituximab/dexamethasone • Ixazomib/rituximab/dexamethasone	<ul> <li>Rituximab</li> <li>Rituximab/cyclophosphamide/dexamethasone ± bortezomib</li> <li>Rituximab/cyclophosphamide/prednisone</li> </ul>	

<sup>a</sup> General Considerations for Systemic Therapy for WM/LPL (WM/LPL-B 1 of 4).

<sup>b</sup> Rapid increases in IgM levels (IgM rebound) have been observed following discontinuation of BTK inhibitors. Consider continuing therapy with the BTK inhibitor until starting the next line of therapy or monitor for IgM rebound after discontinuation of BTK inhibitors.



### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

	DR PREVIOUSLY TREATED WM/LPL <sup>a</sup> Alphabetical and does not indicate preference)
Preferred Regimens • Bendamustine/rituximab • Ibrutinib <sup>b</sup> ± rituximab (category 1) • Rituximab/cyclophosphamide/dexamethasone • Zanubrutinib <sup>b</sup> (category 1)	
Other Recommended Regimens • Acalabrutinib <sup>b</sup> • Bortezomib/dexamethasone/rituximab • Ixazomib/rituximab/dexamethasone	<ul> <li>Rituximab/cyclophosphamide/prednisone</li> <li>Venetoclax</li> </ul>
<u>Useful in Certain Circumstances</u> • Bendamustine • Cladribine ± rituximab <sup>c</sup> • Everolimus • Fludarabine ± rituximab <sup>c</sup>	<ul> <li>Fludarabine/cyclophosphamide/rituximab<sup>c</sup></li> <li>Pirtobrutinib</li> <li>Rituximab</li> <li>RCHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone)</li> </ul>
<ul> <li>Hematopoietic Cell Transplant</li> <li>In selected patients HCT may be appropriate with either:</li> <li>Allogeneic HCT (ablative or nonablative)<sup>d</sup></li> <li>Autologous HCT</li> </ul>	

<sup>a</sup> <u>General Considerations for Systemic Therapy for WM/LPL (WM/LPL-B 1 of 4)</u>.

<sup>b</sup> Rapid increases in IgM levels (IgM rebound) have been observed following discontinuation of BTK inhibitors. Consider continuing therapy with the BTK inhibitor until starting the next line of therapy or monitor for IgM rebound after discontinuation of BTK inhibitors.

<sup>c</sup> May be associated with disease transformation and/or development of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) in patients with WM.

<sup>d</sup> Should ideally be undertaken in the context of a clinical trial.

Note: All recommendations are category 2A unless otherwise indicated.

References

National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

NCCN Guidelines Index Table of Contents Discussion

#### REFERENCES

Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib-dexamethasone, rituximab, and cyclophosphamide as first-line treatment for Waldenström's Macroglobulinemia: A prospectively randomized trial of the European Consortium for Waldenström's Macroglobulinemia. J Clin Oncol 2023;41:2607-2616.

Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: Final analysis from the randomized phase III iNNOVATE study. J Clin Oncol 2022;40:52-62.

Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol 2020;7:e827-e837.

Castillo JJ, Allan JN, Siddiqi T, et al. Venetoclax in previously treated Waldenström macroglobulinemia. J Clin Oncol 2022;40:63-71.

Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenström macroglobulinemia: long-term follow-up. Blood Adv 2020;4:3952-3959.

Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia 2022;36:532-539.

Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom's macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344-3349.

Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood 2019;134:2022-2035.

Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333.

Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-2055.

Ghobrial IM, Gertz M, Laplant B, et al. Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1408-1414.

Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-1428.

Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116-120.

Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113:4163-4170.

Owen R, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet 2019;7:e112-e121.

Owen RG, Kyle RA, Stone MJ, et al. Update from the VIth International Workshop on Waldenström macroglobulinaemia. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol 2013;160:171-176.

Palomba ML, Patel MR, Eyre TA, et al. Efficacy of pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in relapsed/refractory Waldenström macroglobulinemia: results from the Phase 1/2 BRUIN study. Blood 2022;140:557-560.

Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-1210. Published correction appears in Lancet 2013;381:1184.

Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020;136:2038-2050.

Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27:3830-3835.

Treon SP, Meid K, Gustine J, et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol 2021;39:565-575.

Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia. Blood 2014;124:503-510.



### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

NCCN Guidelines Index **Table of Contents** Discussion

#### IWWM-11 RESPONSE CRITERIA FOR ASSESSMENT OF DISEASE RESPONSE IN WM/LPL<sup>1</sup>

Response <sup>a</sup>	Serum Monocional IgM	Serum IgM Level	Bone Marrow Aspirate and Trephine Biopsy	Extramedullary disease
Complete Response (CR)	Absence of monoclonal IgM protein by SPEP and IFX.	Within normal range	Normal morphology; no evidence of LPL involvement.	Absence of extramedullary disease if present at baseline. See criteria for determination of resolution of extramedullary disease. <sup>e</sup>
Very good partial response (VGPR)		≥90% reduction in serum IgM levels or within normal range		
Partial response (PR)		≥50% to <90% reduction in serum IgM levels		
Minor response (MR)		≥25% to <50% reduction in serum IgM levels		
Stable disease (SD)		<25% reduction to <25% increase in serum IgM levels		
Progressive disease (PD)		≥25% increase in serum IgM levels with a minimum increase of 500 mg/dL from nadir. Reconfirmation is required by 2 sequential (back-to-back) measurements if the serum IgM is being used to support PD. Demonstration of PD by imaging does not require re-confirmation. <sup>b,C</sup>		Any new lesion (>1.5 cm in any axis) or unequivocal evidence of an increase by > 50% in any axis to >1.5 cm in size of previously involved extramedullary disease sites from their nadir measurements. Any new lesion consistent with transformed disease.
Nonevaluable (NE)		Suspected IgM flare or IgM rebound, absence of data or suspected error in data reporting <sup>d</sup>		

<sup>1</sup> Reproduced with permission. Treon SP, Tedeschi A, San-Miguel J, et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on

 diagnostic and response criteria. Semin Hematol 2023;60:97-106.
 <sup>a</sup> Categorical response assessment for CR, VGPR, PR, MR or SD assumes no signs or symptoms consistent with disease progression are present. The overall response rate includes MR, PR, VGPR, and CR responses, whereas the major response rate includes PR, VGPR and CR responses.
 <sup>b</sup> Re-confirmation of CR, VGPR, PR, MR, or SD is not required. Progressive disease (PD) must be re-confirmed if the IgM is being used to support PD. To meet criteria for progressive disease, a ≥25% increase in serum IgM level with a minimum serum IgM increase of 500 mg/dL from the nadir is required on 2 sequential (back-to-back) measurements. In the event an IgM measurement meets PD criteria, and the subsequent measurement does not, the patient will not have met PD criteria until 2 back-to-back measurements. PD Demonstration of CR. PD by imaging does not require re-confirmation. In the event of discordant response findings, that is, IgM measurement shows a response but imaging shows PD related to WM, then the assessment should be considered PD.

<sup>c</sup> Suspected IgM flare or IgM rebound related to therapy will not be considered as progressive disease. <sup>d</sup> A nonevaluable response assessment should be specified in cases of suspected IgM flare or IgM rebound; absence of data, or suspected error in data reporting (ie, contradictory central vs local laboratory measurements).

<sup>e</sup> For CR attainment, normalization of extramedullary disease if present at baseline will be considered complete resolution or decrease in size of lymph nodes (<1.5 cm) or decrease in the size of spleen (<15 cm), or complete resolution of any other non-lymph node or non-splenic extramedullary mass(es) related to WM disease consistent with revised response criteria for malignant lymphoma. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579-586.




### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

NCCN Guidelines Index Table of Contents Discussion

#### MANAGEMENT OF BING NEEL SYNDROME

#### WORKUP



Radiotherapy

<sup>a</sup> Rituximab can be added to these regimens if systemic control is needed.

<sup>b</sup> Response criteria per Minnema MC, et al. Haematologica 2017;102:43-51.

National Comprehensive Cancer NCCN **Network**<sup>®</sup>

### **NCCN Guidelines Version 1.2025** Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

#### NCCN Guidelines Index Table of Contents Discussion

#### **ABBREVIATIONS**

AML	acute myeloid leukemia
AS-PCR	allele-specific polymerase chain reaction
BUN	blood urea nitrogen
СВС	complete blood count
СМР	comprehensive metabolic panel
CNS	central nervous system
CR	complete response
CSF	cerebrospinal fluid
DLBCL	diffuse large B-cell lymphoma
EMG	electromyogram
GM1	monosialotetrahexosylganglioside
HCT HIV	hematopoietic cell transplantation human immunodeficiency virus

IgA IgG IgM IHC IPSS	immunoglobulin A immunoglobulin G immunoglobulin M immunohistochemistry International Prognostic Scoring
	System
LDH	lactate dehydrogenase
LFT	liver function test
LPL	lymphoplasmacytic lymphoma
MAG	myelin-associated glycoprotein
MDS	myelodysplastic syndrome
MGUS	monoclonal gammopathy of undetermined significance
MR	minor response
NE	nonevaluable
NCS	nerve conduction study

PD PJP PR	progressive disease pneumocystis jirovecii pneumonia partial response
RBC	red blood cell
SD	stable disease
SIFE	serum immunofixation electrophoresis
SPEP	serum protein electrophoresis
UIFE	urine immunofixation electrophoresis
UPEP	urine protein electrophoresis
VGPR	very good partial response
WM	Waldenström macroglobulinemia

polymerase chain reaction

PCR

ICCN	National Comprehensive Cancer Network®
------	---

### **NCCN Guidelines Version 1.2025** Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

NCCN Categories of Evidence and Consensus		
Category 1	Based upon high-level evidence (≥1 randomized phase 3 trials or high-quality, robust meta-analyses), there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.	
Category 2A	Based upon lower-level evidence, there is uniform NCCN consensus (≥85% support of the Panel) that the intervention is appropriate.	
Category 2B	Based upon lower-level evidence, there is NCCN consensus (≥50%, but <85% support of the Panel) that the intervention is appropriate.	
Category 3	Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.	
All recommendations are category 2A unless otherwise indicated		

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference			
Preferred intervention	Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability.		
Other recommended intervention	Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes.		
Useful in certain circumstances	Other interventions that may be used for selected patient populations (defined with recommendation).		

All recommendations are considered appropriate.



### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

**Discussion** This discussion corresponds to the NCCN Guidelines for Waldenström Macroglobulinemia/Lymphoblastic Lymphoma. Last updated: December 3<sup>rd</sup>, 2023.

#### Table of Contents

Overview	MS-2			
Literature Search Criteria and Guidelines Update MethodologyMS-2				
Diagnosis	MS-2			
Workup	MS-2			
Essential Tests	MS-2			
Tests Useful Under Certain Circumstances	MS-3   SSION \ \			
Primary Therapy Regimens for WM/LPL	MS-4			
Preferred Regimens for Primary Therapy	MS-5 to in			
Other Recommended Regimens for Primary Therapy	MS-7			
Assessment of Response to Primary Treatment	MS-9			
Follow-up After Primary Treatment	MS-9 1035 //			
Therapy for Previously Treated WM	MS-9			
References	MS-15			

National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

#### Overview

Waldenström macroglobulinemia (WM) is a B-cell disorder characterized primarily by bone marrow infiltration with lymphoplasmacytic cells and immunoglobulin M (IgM) monoclonal gammopathy.<sup>1</sup> This condition is defined as "lymphoplasmacytic lymphoma" (LPL) by the Revised European-American Lymphoma (REAL) and World Health Organization (WHO) classification systems.<sup>2,3</sup> WM is a rare disorder with approximately 1000 to 1500 new cases diagnosed annually in the United States.<sup>4</sup>

## Literature Search Criteria and Guidelines Update Methodology

Prior to the update of this version of the NCCN Clinical Practice Guidelines (NCCN Guidelines<sup>®</sup>) for Waldenström Macroglobulinemia, an electronic search of the PubMed database was performed to obtain key literature in WM/LPL using the following search terms: Waldenström macroglobulinemia OR lymphoplasmacytic lymphoma. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.<sup>5</sup>

The search results were narrowed by selecting studies in humans published in English. Results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Practice Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The data from key PubMed articles as well as articles from additional sources deemed as relevant to these guidelines as discussed by the panel during the Guidelines update have been included in this version of the Discussion section. Recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion. The complete details of the Development and Update of the NCCN Guidelines are available at <u>www.NCCN.org</u>.

### Diagnosis

Key to the diagnosis of WM/LPL is the demonstration of bone marrow infiltration by a lymphoplasmacytic cell population manifested by small lymphocytes with evidence of plasmacytoid/plasma cell differentiation. The bone marrow infiltration should be supported by immunophenotypic studies (flow cytometry and/or immunohistochemistry) showing the following profile: slgM+, CD19+, CD20+, CD22+.<sup>1</sup> According to the current WHO classification, the lymphocytes in WM are typically negative for CD5, CD10, and CD23.<sup>6</sup> However, this should not exclude diagnosis as exceptions occur and approximately 10% to 20% of cases may express CD5, CD10, or CD23.<sup>7,8</sup> *MYD88* (L265P) mutations are present in greater than 90% of patients with WM,<sup>9</sup> and can help differentiate WM/LPL from IgM myeloma or marginal zone lymphoma.

### Workup

### **Essential Tests**

History and physical (H&P) examination are essential components of initial evaluation. The essential laboratory studies include complete blood count (CBC) with differential, peripheral blood smear examination, and comprehensive metabolic panel (CMP). CMP includes serum blood urea nitrogen (BUN)/creatinine, electrolytes, albumin, calcium, and liver function tests (LFTs) to assess kidney and liver function.<sup>10</sup>

To establish the diagnosis of WM, it is necessary to demonstrate IgM monoclonal protein in the serum and histologic evidence of lymphoplasmacytic cells in the bone marrow.<sup>1</sup> Serum protein electrophoresis (SPEP), serum quantitative immunoglobulins, and serum immunofixation electrophoresis (SIFE) are used to identify and quantify the M-protein (IgM). While detection of a monoclonal IgM protein in the

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

serum is a diagnostic criterion for WM, this monoclonal IgM may be found clinically either in the setting of clinical WM, IgM monoclonal gammopathy of undetermined significance (IgM MGUS), or IgM multiple myeloma. It is important to make this distinction during diagnosis. Approximately 5% of patients with LPL can secrete non-IgM paraproteins (e.g., IgG, IgA, kappa, lambda) or be non-secretory and should be managed like WM.

The International Prognostic Scoring System for WM (IPSSWM) is useful for prognostication of WM at first-line treatment initiation.<sup>11,12</sup> Its value in making treatment-related decisions remains to be clarified.<sup>11</sup>

Bone marrow is almost always involved in WM; therefore, a unilateral bone marrow aspirate and biopsy should be performed to document clonal lymphoplasmacytic cell population and confirmed by immunohistochemistry and/or flow cytometry.<sup>1,6</sup> Multiparametric flow cytometry may provide additional data on the immunophenotypic characterization of WM.<sup>13</sup>

The bone marrow aspirate should be tested for *MYD88* (L265P) mutation. Whole genome sequencing of bone marrow LPL cells has identified *MYD88* (L265P) as a commonly recurring mutation in patients with WM.<sup>9,14,15</sup> *Absence* of *MYD88* mutations should not be used to exclude diagnosis of WM if other criteria are met.<sup>16</sup> The NCCN Panel recommends allele-specific polymerase chain reaction (AS-PCR) for *MYD88* (L265P) detection.

CT scans of the chest, abdomen, and pelvis with intravenous (IV) contrast and/or PET-CT at time of diagnosis are useful to properly stage the patient and can assess adenopathy, splenomegaly, and other extramedullary disease sites.

#### **Tests Useful Under Certain Circumstances**

IgM is a pentamer and a common cause of hyperviscosity. Therefore, evaluation for characteristic clinical signs and symptoms of serum viscosity should be done at diagnosis. Many patients with WM will exhibit an elevated serum viscosity level of over 1.8 centipoise (cP). Patients typically become symptomatic at serum viscosity levels of over 4.0 cP. However, in some patients, lower levels of serum viscosity can cause retinal changes and hemorrhages that may necessitate intervention.<sup>17</sup> Serum viscosity results should not be used as the sole criterion for intervention, in part due to long turnaround time and potential technical issues.

In less than 10% of patients with WM, monoclonal IgM may present with cold agglutinin activity, where the monoclonal IgM interact with specific red cell antigens below physiological temperatures, producing chronic hemolytic anemia.<sup>18</sup> The cold agglutinin titers are greater than 1:1000 in most cases. In up to 20% of patients with WM, the monoclonal IgM may behave as a cryoglobulin (type I) but will be symptomatic in less than or equal to 5% of the cases. The presence of cold agglutinins or cryoglobulins may affect determination of IgM levels; therefore, testing for cold agglutinins and cryoglobulins should be performed at diagnosis.<sup>19</sup>

When suspected, cryocrit, a test for cryoglobulins, should be obtained. The presence of cryoglobulins may render falsely low serum IgM levels. In such situations, maintaining the serum sample in a warm bath will provide a more reliable serum IgM level measurement.<sup>20</sup>

Twenty-four-hour urine for total protein, creatinine clearance, urine protein electrophoresis (UPEP), and urine immunofixation electrophoresis (UIFE) may be useful.

NCCN NCCN NCCN Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

Patients with WM and peripheral neuropathy may harbor antibodies against myelin-associated glycoprotein (MAG) or other glycoproteins or lipids.<sup>19,21</sup>

Serum anti-MAG antibodies can be evaluated in patients with sensory peripheral neuropathies<sup>22</sup>; in those with motor neuropathy, anti-ganglioside M1 (GM1) antibodies may also be evaluated. In patients with peripheral neuropathy, referral for neurologic consultation should be considered. Nerve conduction studies (NCS) or electromyography (EMG) may help determine if neuropathy is related to the monoclonal process or other causes.<sup>23</sup>

The median age at the time of WM diagnosis ranges from 60 to 75 years.<sup>19,24,25</sup> Therefore, frailty assessment should be considered prior to treatment of older adults with WM as per NCCN Guidelines for Older Adult Oncology (available at <u>NCCN.org</u>).

The manifestation of neurological deficits is ambiguous and could be the result of underlying comorbidities. If CNS involvement is suspected in individuals with WM; imaging studies, CSF analysis, or tissue biopsy are needed to investigate Bing-Neel syndrome.

### Asymptomatic or Minimally Symptomatic

Waldenström macroglobulinemia may be preceded by asymptomatic disease states such as IgM monoclonal gammopathy of undetermined significance (IgM MGUS) or smoldering WM (SWM).<sup>26</sup> Approximately 1.5% of patients with IgM MGUS and 12% of those with SWM have disease progression to WM per year.<sup>9,27-29</sup> The risk of disease progression is estimated using an asymptomatic risk score calculator, which takes the following diagnostic measurements into consideration: bone marrow involvement (%), serum IgM level (mg/dl), serum beta-2- microglobulin level (mg/dl), and serum albumin level (g/dl).<sup>3</sup> Based on the risk score, the

risk of disease progression is categorized into low-risk, intermediate-risk, and high-risk, with a median time to progression to symptomatic disease of 9.2 years, 4.8 years, and 1.8 years, respectively. The frequency of follow-up varies based on the risk status. Follow-up includes monitoring with diagnostic testing, including CBC, CMP, SPEP, and serum immunoglobulins, every 12 months for low risk, every 6 months for intermediate risk, and every 3 months for high risk.

### Primary Therapy Regimens for WM/LPL

According to the NCCN WM/LPL Panel, treatment should be initiated for patients with a diagnosis of WM/LPL only in those who are symptomatic. The indicative symptoms of treatment include hyperviscosity; neuropathy; symptomatic adenopathy or organomegaly; amyloidosis; cryoglobulinemia; cold agglutinin disease; anemia; B-symptoms and presence of cytopenia.<sup>11,30-32</sup> Importantly, high IgM level per se should not be considered a criterion for initiation of therapy in the absence of other indications. The NCCN panel notes that it is important to rule out symptoms related to comorbidities before treatment initiation and detection of cold agglutinins or cryoglobulins in the absence of symptoms does not represent a criterion to treat, whereas treatment should be considered in asymptomatic patients with serum IgM level >6000 mg/dL.

Since WM is a rare disease, few randomized trials and limited data comparing different treatment approaches exist. Therefore, the treatment for WM has been primarily adopted from data derived from phase II or retrospective studies.

According to the NCCN Panel, for patients requiring immediate disease control, such as those with symptomatic hyperviscosity, initial plasmapheresis is recommended.<sup>33</sup> After plasmapheresis, systemic treatment should be initiated as soon as possible.

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

Agents that limit future treatment options should be avoided during initial therapy. Exposure to continuous oral alkylator therapy or nucleoside analogs should be avoided prior to stem cell harvest if an autologous stem cell transplant (SCT) is being considered. Nucleoside analogs are associated with an increased risk of disease transformation, development of myelodysplastic syndromes (MDS), and secondary acute myeloid leukemia (AML).<sup>34,35</sup> Exposure to nucleoside analogs should be limited, particularly in younger patients who may be potential SCT candidates.

The NCCN Panel recommends monitoring of serum IgG levels during therapy. Herpes zoster prophylaxis should be considered for patients receiving proteasome inhibitor-based regimens and nucleoside analogs.

Hepatitis B virus (HBV) reactivation is common in patients with hematologic malignancies. The NCCN Panel recommends screening for HBV infection by testing for hepatitis B surface antigen (HBsAg) or antibody to hepatitis B core antigen (HBcAb) before starting therapy with carfilzomib or anti-CD20 monoclonal antibodies. Prophylactic antiviral therapy with entecavir is recommended for those who have HBsAg to prevent HBV reactivation. In those with resolved HBV infection, who have antibodies to hepatitis B core antigen (HBcAb), the panel prefers prophylaxis with antiviral therapy. However, if there is a concurrent highlevel hepatitis B surface antibody, monitoring serially for hepatitis B viral load and giving antiviral therapy as soon as HBV DNA is detectable is also an option.

All treatment options for WM/LPL are listed alphabetically in the NCCN Guidelines. The NCCN Panel has categorized WM therapy regimens as: "preferred regimens," "other recommended regimens," and regimens "useful under certain circumstances." The purpose of classifying regimens is to provide guidance on treatment selection considering the relative efficacy, toxicity, and other factors that play into treatment selection, such as pre-existing comorbidities (e.g., peripheral neuropathy, rituximab

intolerance). The NCCN Panel Members strongly encourage treatment in the context of a clinical trial when possible.

#### **Preferred Regimens for Primary Therapy**

Bendamustine/Rituximab: Rituximab, a monoclonal antibody that targets the B-lymphocyte antigen CD20, has been used successfully in the treatment of WM, because CD20 is expressed on lymphoplasmacytic cells in patients with WM. The Study Group Indolent Lymphomas (StiL) examined the activity of bendamustine plus rituximab (BR) versus cyclophosphamide, doxorubicin, vincristine, prednisone plus rituximab (RCHOP) in a large, randomized, multicenter phase III trial of previously untreated patients with indolent non-Hodgkin lymphoma (NHL).<sup>36</sup> Included in this study were 41 patients with WM/LPL, 40 of whom were available for response assessment.<sup>36</sup> After a median follow-up of 45 months, the median progression-free survival (PFS) was significantly longer with BR treatment, 69.5 versus 28.5 months with RCHOP.<sup>37</sup> BR was associated with a lower incidence of grade 3 or 4 neutropenia, infectious complications, and alopecia in this study. These results suggest that BR may be a preferable option to RCHOP as primary therapy for WM.<sup>37</sup> The results of the StiL NHL-2008 MAINTAIN trial, demonstrate a median PFS of 65.3 months in those receiving bendamustine and rituximab, which is consistent with the results of the StiL NHL1-2003 trial (69.5 months).38

Pneumocystis jirovecii pneumonia [PJP] prophylaxis should be considered for patients receiving bendamustine/rituximab.

The NCCN Panel has included bendamustine/rituximab as a Preferred Regimen for Primary Therapy.

*Bortezomib/Dexamethasone/Rituximab*: Bortezomib has shown excellent activity in the management of WM as a single agent,<sup>39</sup> in combination with rituximab,<sup>40</sup> or in combination with rituximab and dexamethasone.<sup>41,42</sup>

#### NCCN National Comprehensive Cancer Network® NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

The study by Waldenström Macroglobulinemia Clinical Trials Group (WMCTG) reported an overall response rate (ORR) of 96%, including 83% of patients achieving a partial response (PR) with the combination of intravenous (IV) bortezomib (using a twice-a-week schedule), along with rituximab and dexamethasone (BDR) in newly diagnosed patients with WM.<sup>41</sup> With a median follow-up of 2 years, 80% of patients remained free of disease progression, including all patients achieving a very good partial response (VGPR) or better. However, grade 3 peripheral neuropathy was observed in 30% of patients. The development of peripheral neuropathy led to premature discontinuation of bortezomib in 61% of patients in this study.

In another multicenter phase II trial, the activity of BDR (using onceweekly IV bortezomib) was evaluated in 59 newly diagnosed symptomatic patients with WM.<sup>43</sup> The ORR was 85% (3% complete response [CR], 7% VGPR, and 58% PR). In 11% of patients, an increase of IgM ( $\geq$ 25%) was observed after administration of rituximab. After 32 months of follow-up, median PFS was 42 months and 3-year overall survival (OS) was 81%. Peripheral neuropathy was observed in 46% (grade  $\geq$ 3 in 7%) of patients; 8% discontinued bortezomib due to neuropathy.<sup>43</sup>

Neuropathy is a primary toxicity observed with bortezomib-based regimens. Therefore, evaluation of patients for the development of bortezomib-related peripheral or autonomic neuropathy is important. Administering bortezomib subcutaneously and once weekly reduces the risk of peripheral neuropathy. Therefore, this is the preferred method of administration. While both weekly and twice-weekly dosing schemas of bortezomib are appropriate, the weekly schema is preferred.

The NCCN Panel has included BDR as a Preferred Regimen for Primary Therapy.

*Ibrutinib with or without Rituximab*: Signaling pathways from the B-cell antigen receptor and Bruton's tyrosine kinase (BTK) are crucial in mediating the growth and survival of B-cell malignancies, including WM.<sup>44</sup>

A phase II trial of ibrutinib monotherapy in patients with symptomatic WM (n = 63) who received at least one prior treatment reported an ORR of 90% (10 with a VGPR, 36 with a PR, 11 with a minor response, none with a CR) and a median time to response of 4 weeks.<sup>45</sup> At 5 years, the PFS and OS rates were 54% and 87%, respectively.<sup>46</sup> *CXCR4* mutations impacted adversely time to response, depth of response and PFS duration. Treatment-related toxic effects of grade 3 or higher included neutropenia (in 16% of patients) and thrombocytopenia (in 11% of patients).<sup>46</sup> Similar results were observed in a phase II study on 30 treatment-naïve WM patients treated with ibrutinib, with an ORR of 100%, a VGPR rate of 30%, and 48-month PFS rate of 76%.<sup>47</sup> Other adverse events associated with ibrutinib include bleeding and arrhythmia. The U.S. Food and Drug Administration (FDA) has approved ibrutinib as single-agent therapy for patients with WM until disease progression or unacceptable toxicity.

The phase III iNNOVATE trial (n = 150) compared both newly diagnosed and patients with relapsed/refractory WM treated with ibrutinib/rituximab or rituximab plus placebo.<sup>48</sup> At 30 months of follow-up, the ibrutinib/rituximab treatment showed an ORR of 95% compared with 48% in those treated with rituximab/placebo. In newly diagnosed patients, treatment with ibrutinib/rituximab demonstrated an improved PFS at 24 months (84%) compared to the rituximab arm (59%) (hazard ratio [HR], 0.34; 95% CI, 0.12–0.95).<sup>48</sup> The rituximab-induced infusion reactions were markedly reduced in the ibrutinib/rituximab arm.<sup>49</sup> At 50 months of follow-up, improvements in PFS were seen with ibrutinib/rituximab (median not reached) over rituximab/placebo (median PFS, 20 months), demonstrating a significant reduction in disease progression or death (HR, 0.25; 95% CI,

NCCN National Comprehensive Cancer Network® NCCN Use Composite Cancer Lympheret Cancer Lymp

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

0.15–0.42; *P* < .0001). The estimated 54-month PFS rates were 68% with ibrutinib/rituximab versus 25% with rituximab/placebo. Median OS was not reached in either treatment arm (HR, 0.81; 95% CI, 0.33–1.99; *P* = .64). The ORR was 92% with ibrutinib/rituximab versus 44% with rituximab/placebo. *CXCR4* mutations affected VGPR rates (23% vs. 44%) but did not impact PFS. The most common grade 3/4 adverse events with ibrutinib/rituximab over the 5-year study period were infections (29%), atrial fibrillation (16%), hypertension (15%), neutropenia (13%), anemia (12%), and pneumonia (11%).<sup>50</sup>

The NCCN Panel has included ibrutinib with or without rituximab as a Preferred Regimen for Primary Therapy (category 1).

*Zanubrutinib*: Zanubrutinib is a BTK inhibitor with a higher affinity to BTK than ibrutinib. In the phase III ASPEN trial, 201 patients with treatmentnaïve or relapsed/refractory WM were randomized 1:1 to receive either zanubrutinib or ibrutinib. All patients had a *MYD88* (L265P) mutation and 26% had a *CXCR4* mutation. There was no statistical difference in VGPR between the zanubrutinib and ibrutinib groups (28% vs. 19%; *P* = .09).<sup>51</sup> The 42-month PFS rate for zanubrutinib was 78% and for ibrutinib was 70% with a HR 0.63 (95% CI 0.36-1.12).<sup>52</sup> Zanubrutinib induced higher VGPR (21% vs. 10%) and 42-month PFS rates (73% vs. 49%) than ibrutinib in patients with *CXCR4* mutations.

The ASPEN safety data comparing zanubrutinib monotherapy showed a decrease in the incidence of atrial fibrillation (4% vs. 17%) and a lower incidence in most non-hematologic adverse events (AEs) compared with ibrutinib. The incidence of hematologic AEs was similar except for neutropenia, in which zanubrutinib was associated with a twofold likelihood of any grade (29% vs. 13%) and grade  $\geq$ 3 (20% vs. 8%) neutropenia compared to ibrutinib. A larger proportion of patients received granulocyte colony-stimulating factor with zanubrutinib compared to ibrutinib.<sup>51</sup>

The NCCN Panel has included zanubrutinib as a Preferred Regimen for Primary Therapy (category 1).

#### Other Recommended Regimens for Primary Therapy

*Bendamustine*: Based on the durable responses seen in previously treated WM, as monotherapy in rituximab-intolerant individuals,<sup>53</sup> bendamustine has been included as an option for primary therapy for WM.

*Carfilzomib/Rituximab/Dexamethasone:* A prospective phase II study studied the combination of carfilzomib/rituximab/dexamethasone in newly diagnosed symptomatic patients (n = 31) with WM/LPL.<sup>54</sup> Long-term follow-up demonstrated an ORR of 87% and a median PFS of 46 months.<sup>55</sup> The study found that the response to this regimen was not impacted by *MYD88* (L265P) mutation status. Rituximab-associated IgM flare (increase of IgM ≥25%) was observed in 23% of patients. No significant peripheral neuropathy was observed in this study. IgA and IgG depletion were commonly observed and necessitated truncation of therapy and/or IV immunoglobulin use in several patients.<sup>54</sup>

The NCCN Panel has included carfilzomib/rituximab/dexamethasone as a treatment option under Other Recommended Regimens for Primary Therapy and noted under general considerations that it can potentially cause cardiac and pulmonary toxicity, especially in older patients.

*Ixazomib/Rituximab/Dexamethasone*: A prospective phase II study, of patients (n = 26) with symptomatic WM studied the combination of ixazomib/rituximab/dexamethasone and found this regimen to be safe and effective as a primary therapy option.<sup>56</sup> All enrolled patients had the *MYD88* (L265P) mutation, and 58% had a *CXCR4* mutation. The median time to response was 8 weeks. The overall, major, and VGPR rates were 96%, 77%, and 19%, respectively, and the median time to response was 8 weeks.<sup>56</sup> The median PFS was 40 months, median duration of response (DOR) was 38 months, and the median time to next treatment (TTNT) was

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

40 months. PFS, DOR, and TTNT were not affected by *CXCR4* mutational profile.<sup>57</sup>

The NCCN Panel has included ixazomib/rituximab/dexamethasone as a treatment option under Other Recommended Regimens for Primary Therapy.

*Rituximab*: Single-agent rituximab is active in patients with WM; however, the response rates of single-agent rituximab using either standard or extended dosing vary between 25% and 45%.<sup>35,58,59</sup> Transient increases in IgM levels (also called the IgM flare) have been reported in 40% to 50% of patients after initiation of rituximab therapy.<sup>60,61</sup> The rituximab-related IgM flare may lead to symptomatic hyperviscosity, as well as worsening of IgM-related neuropathy, cryoglobulinemia, and other IgM-related complications. These levels may persist for months and do not indicate treatment failure but may necessitate plasmapheresis to reduce IgM levels. Prophylactic plasmapheresis can be considered in patients with high IgM levels (typically 4000 mg/dL or higher)<sup>62</sup> before rituximab exposure to minimize the risk of symptomatic IgM flare. The risk of IgM flare may be decreased in patients receiving rituximab in combination with other agents.<sup>41</sup> Rituximab may be reasonable for treating patients with IgM anti-MAG antibody-related neuropathies.<sup>63</sup>

*Rituximab/Cyclophosphamide/Dexamethasone*: In a prospective study of people with untreated WM (n = 72), treatment with rituximab/cyclophosphamide/dexamethasone (R-CD) resulted in an ORR of 83% that included a 7% CR and a 67% PR. The 2-year PFS was 67% for all evaluable individuals and 80% for responders. The R-CD regimen was well-tolerated, with 9% of those experiencing grade 3 or 4 neutropenia and approximately 20% of individuals experiencing some form of toxicity related to rituximab.<sup>64</sup> The 8-year OS rates based on the IPSSWM risk status for WM were 100%, 55%, and 27% for low-, intermediate-, and high-risk disease, respectively (P = .005).<sup>65</sup> In a

retrospective analysis of outcomes after treatment with R-CD in 50 people with untreated WM, the ORR was 96% and the median PFS was 34 months. The response rate and duration of response were independent of *MYD88* mutational status.<sup>66</sup>

#### The NCCN Panel has included

rituximab/cyclophosphamide/dexamethasone as a treatment option under Other Recommended Regimens for Primary Therapy.

*Rituximab/Cyclophosphamide/Prednisone*: The use of cyclophosphamide/prednisone/rituximab (CP-R) has been shown to be analogous to the more intense cyclophosphamide-based regimens with lesser treatment-related complications.<sup>67</sup> A single institutional retrospective study examined the outcomes of symptomatic patients with WM who received CHOP-R (n = 23), cyclophosphamide/vincristine/prednisone plus rituximab (CVP-R; n = 16), or CP-R (n = 19). Baseline characteristics were similar for all three cohorts except for serum IgM levels, which were higher in patients treated with CHOP-R ( $P \le .015$ ). The ORR and CR to the three regimens were: CHOP-R (ORR, 96%; CR, 17%); CVP-R (ORR, 88%; CR, 12%); and CP-R (ORR, 95%; CR, 0%). A higher incidence for neutropenic fever and treatment-related neuropathy were reported for CHOP-R and CVP-R versus CP-R ( $P \le .03$ ).<sup>67</sup>

*Maintenance Therapy:* Retrospective data supported PFS and OS benefits with maintenance rituximab after a rituximab-containing regimen.<sup>68,69</sup> However, a recent phase III study in WM patients who attained PR or better after six cycles of bendamustine/rituximab did not show PFS or OS benefit of maintenance rituximab over observation following induction therapy.<sup>38</sup> In the subset analysis, patients older than 65 and patients with high IPSS risk for WM may have benefited from maintenance.<sup>38</sup>

National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

### Assessment of Response to Primary Treatment

Response to therapy in WM is defined by reduction in the IgM protein. According to the updated summary of response categories from the Eleventh International Workshop on WM,<sup>70</sup> a minor response is an IgM reduction of at least 25%; a PR is defined as a greater than or equal to 50% reduction in IgM immunoglobulin; a VGPR is a greater than or equal to 90% reduction in IgM immunoglobulin; and a CR is immunofixation negativity in the serum along with resolution of extramedullary disease and clearance of the bone marrow. Stable disease is defined as a less than 25% reduction and less than 25% increase of serum IgM by electrophoresis without progression of adenopathy/organomegaly, cytopenias, or clinically significant symptoms due to disease and/or signs of WM. Progressive disease is defined as a 25% increase in serum IgM by protein electrophoresis confirmed by a second measurement. The updated summary of response categories and criteria from the Eleventh International Workshop on WM,<sup>70</sup> has been included in the NCCN Guidelines (see Table on page WM/LPL-C).

An important concern with the use of IgM as a surrogate marker of disease is that it can fluctuate independently of tumor cell killing. Rituximab induces a spike or flare in serum IgM levels that can occur when used as monotherapy and in combination with other agents and lasts for several weeks to months.<sup>19,60,61</sup> Conversely, bortezomib and ibrutinib can suppress IgM levels independent of killing tumor cells in certain patients.<sup>71,72</sup> One study showed that residual IgM-producing plasma cells are spared and persist in patients treated with selective B-cell–depleting agents such as rituximab, thus potentially skewing the relative response and assessment to treatment.<sup>73</sup> Therefore, in circumstances where the serum IgM levels appear to be out of context with the patient's clinical progress, a bone marrow biopsy should be considered to clarify the patient's underlying disease burden.

### **Follow-up After Primary Treatment**

After primary therapy, the NCCN Panel recommends assessing the response to treatment using consensus panel criteria outlined on page WM/LPL-C.

The goal of treatment is symptom relief and reducing the risk of organ damage. When assessing responses, it is important to recognize that with some agents, responses (reduction of IgM) to initial therapies are often delayed and may result in underestimation of response.

If the primary treatment was with a fixed duration chemoimmunotherapy regimen, patients should be observed for disease progression with tests including CBC, CMP, and IgM every 3 months for 2 years, then every 4–6 months for an additional 3 years, then every 6–12 months. Without symptoms, progression based on serum IgM levels alone should not be a reason to restart treatment.

If treatment is initiated with a BTK inhibitor regimen, treatment should be continued until disease progression or unacceptable toxicity. Rapid increases in IgM levels (IgM rebound) have been observed following discontinuation of BTK inhibitors. Consider continuing therapy with the BTK inhibitor until starting the next line of therapy or monitor for IgM rebound after discontinuing BTK inhibitors.

If symptoms persist or there is no response to primary treatment, an alternate therapy may be administered. If there is disease transformation to an aggressive lymphoma, see <u>NCCN Guidelines for B-Cell Lymphomas</u>.

### Therapy for Previously Treated WM

Many patients inevitably experience relapse after initial therapy and require further treatment.<sup>74</sup> According to the NCCN Guidelines, administering the same regimen used for primary treatment is reasonable as therapy for relapsed disease, especially if the regimen was well-

National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

tolerated and the patient had a prolonged response. The panel notes that caution should be used when re-treating with myelosuppressive regimens due to cumulative toxicities.

For patients with remissions lasting less than 24 months or who show progressive disease/resistance to a first-line regimen, second-line treatment may include agents of a different class of drugs, either alone or in combination. In addition, it is important to avoid exposure to stem celldamaging agents, such as an alkylator or nucleoside analogs, in patients who are candidates for autologous SCT. Regimens that are not toxic to stem cells must be offered, especially if stem cells have not previously been harvested. All regimens listed under primary treatment options are effective options for consideration in patients with previously treated WM.

#### Preferred Regimens for Previously Treated WM/LPL

Bendamustine/Rituximab: Bendamustine-based therapy is effective in relapsed/refractory WM because it produces high and durable response rates. A phase II study of patients with relapsed/refractory WM who received bendamustine-based therapy reported an ORR of 83.3%.<sup>53</sup> The median PFS in patients with refractory WM/LPL was 13.2 months.<sup>53</sup> A phase I/II study analyzed the outcome of bendamustine plus rituximab in patients with relapsed/refractory WM. Patients had previously received a median number of 2 lines of treatment (range 1-5). The ORR reported was 80.2%.<sup>75</sup> Another study evaluated the efficacy of BR and R-CD. Of the 160 patients, 60 received BR (43 with relapsed/refractory WM), and 100 received R-CD (50 had relapsed/refractory WM). In patients with relapsed/refractory WM, ORR with BR was 95% versus 87% with R-CD, P = .45; median PFS with BR was 58 versus 32 months with R-CD (2-year PFS was 66% vs. 53%; P = .08).<sup>76</sup>

Bendamustine combined with rituximab is listed as one of the preferred options for relapsed/refractory disease and single agent bendamustine is listed under Other Recommended Regimens in the algorithm.

*Bortezomib/Dexamethasone/Rituximab:* The use of bortezomib as therapy for relapsed disease is associated with an ORR of 60% when administered as a single agent, and of 70% to 80% when in combination with rituximab<sup>39,71,72,77-79</sup> with or without dexamethasone.<sup>80</sup> Grade 3 peripheral neuropathy may occur in 30% of patients using the twice-aweek dosing schedule of bortezomib and in 10% of patients receiving once-a-week dosing. Bortezomib/dexamethasone/rituximab is listed as one of the preferred options for primary therapy as well as previously treated WM/LPL.

*Ibrutinib/Rituximab:* Based on the results of the phase III iNNOVATE trial that included patients with relapsed/refractory WM (trial details listed under Primary Therapy for WM/LPL), the NCCN Panel has added it as one of the Preferred Regimens for Therapy for Previously Treated WM/LPL (category 1).

*Rituximab/Cyclophosphamide/Dexamethasone*: A phase II study investigated symptomatic patients with WM (n=100), of whom 50 patients received at least one cycle of therapy for relapsed/refractory WM and 50 patients received at least one cycle of the same regimen for newly diagnosed WM.<sup>66</sup> In the relapsed/refractory setting, the median PFS reported was 32 months (95% CI: 15–51) with a 2- and 4-year PFS rates of 54% and 34%, respectively.<sup>66</sup>

#### The NCCN Panel has included

rituximab/cyclophosphamide/dexamethasone as one of the Preferred Regimens for Therapy for Previously Treated WM/LPL

NCCN NCCN Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

*Zanubrutinib:* Based on the phase III ASPEN trial results, that included relapsed/refractory WM (trial details listed under Primary Therapy for WM/LPL). The NCCN Panel has included zanabrutinib as one of the Preferred Regimens for Therapy for Previously Treated WM/LPL (category 1).

#### Other Recommended Regimens for Previously Treated WM/LPL

*Acalabrutinib:* Acalabrutinib is another BTK inhibitor that may be considered. A single-arm phase II trial analyzed the usage of acalabrutinib in 106 patients with treatment-naïve or relapsed/refractory WM. Out of the total 106 enrolled, 14 patients (13%) were treatment-naïve, 41 patients (39%) had received 3 or more prior therapies, and 33 patients (31%) had refractory disease. In treatment-naïve patients, the 24-month OS was 92% and the 24-month PFS was 90%. In relapsed/refractory patients, the 24-month OS was 89% and the 24-month PFS was 82%. The most common grade 3/4 adverse events were neutropenia (16%), pneumonia (7%), anemia (5%), and lower respiratory tract infection (5%).<sup>81</sup> The NCCN Panel has included acalabrutinib as a treatment option under Other Recommended Regimens for Previously Treated WM/LPL.

*Ixazomib/Rituximab/Dexamethasone*: The results of a phase I/II study in patients (n=59) who had received a median of two prior therapies treated with ixazomib/rituximab/dexamethasone showed an ORR of 71% (14% VGPR 37% PR, and 20% minor response) after 8 cycles.<sup>82</sup> The median duration of response reported was 36 months. The PFS and OS were 56% and 88%, respectively, after a median follow-up of 24 months.<sup>82</sup>?

Based on this data, the NCCN Panel has included *ixazomib/rituximab/dexamethasone* as a treatment option under Other Recommended Regimens for Previously Treated WM/LPL. *Rituximab:* Treatment with single-agent rituximab has been reported to produce 40% to 50% response rates.<sup>58,61,83</sup> The NCCN Panel has included single-agent rituximab as a treatment option under Other Recommended Regimens for Previously Treated WM/LPL.

*Rituximab/Cyclophosphamide/Prednisone:* A retrospective study examined the outcomes of patients with WM who received 3 separate rituximab-based regimens.

Rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone (RCHOP); n = 23), rituximab/cyclophosphamide/vincristine/ prednisone (RCVP); n = 16), or rituximab/cyclophosphamide/prednisone (RCP); n = 19).<sup>67</sup> The results reported the following ORR and CR rates to the regimens: RCHOP (ORR, 96%; CR, 17%); RCVP (ORR 88%; CR 12%); RCP (ORR, 95%; CR, 0%). Therapy-related adverse events such as neutropenic fever and treatment-related neuropathy were higher for RCHOP and RCVP compared with RCP (P < .03).<sup>67</sup>

The NCCN Panel has included RCP as a treatment option under Other Recommended Regimens for Previously Treated WM/LPL.

*Venetoclax:* Venetoclax is an oral BCL2 antagonist approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). BCL2 is an anti-apoptotic protein that is shown to be overexpressed in primary WM cells.<sup>84</sup> A phase II trial analyzed venetoclax monotherapy in 33 patients with previously treated WM. All patients had a *MYD88* (L265P) mutation, and 17 patients (53%) had a *CXCR4* mutation. At median follow-up of 33 months, the median PFS was 30 months. At time of data cutoff, the 30-month OS was 100% and the ORR was 84%. There was no difference in major response rate nor PFS on the basis of *CXCR4* mutational status. The most common grade 3/4 adverse event was neutropenia (42%).<sup>85</sup> The NCCN Panel has included venetoclax as a treatment option under Other Recommended Regimens for Previously Treated WM/LPL.

NCCN National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

## Regimens Useful in Certain Circumstances for Previously Treated WM/LPL

*Cladribine Alone or with Rituximab*: Cladribine, a nucleoside analogue, has been studied alone or in combination with rituximab and found to induce good ORRs with prolonged survivals.<sup>86-88</sup> In a phase II trial of cladribine with rituximab in 29 patients with newly diagnosed or previously treated WM, reported ORRs and CR rates were 90% and 24%, respectively. Cladribine alone or with rituximab is listed under Useful in Certain Circumstances for Therapy for Previously Treated WM/LPL.

*Everolimus:* Everolimus, an inhibitor of mTOR, is a potentially effective drug in treating WM, with high single-agent activity but substantial toxicity. With a different mechanism of action, it offers an alternate therapeutic strategy for patients with relapsed/refractory WM. A phase II trial of single-agent everolimus was initiated in 60 patients with relapsed or relapsed/refractory WM.<sup>89</sup> The response rate (minor response or better) was 73% with a PR rate of 50% and a minor response rate of 23%.<sup>90</sup> The median PFS was 21 months. Grade 3- or 4-related toxicities were reported in 67% of patients. Dose reductions due to toxicity were made in 62% of patients. The most commonly reported hematologic toxicities were cytopenias. Pulmonary toxicity was seen in 5% of patients.<sup>90</sup> The study reported that the patients who achieved a PR responded after a median of 2 months of treatment. Everolimus is listed in the algorithm under Useful in Certain Circumstances for Therapy for Previously Treated WM/LPL.

*Fludarabine alone or with Rituximab:* Like cladribine, fludarabine is a nucleoside analogue and has been studied alone or in combination with rituximab and/or cyclophosphamide in patients with newly diagnosed WM. A recent phase III trial showed that monotherapy with fludarabine was more effective than chlorambucil in terms of PFS (36.3 vs. 27.1 months; P = .012), duration of response (38.3 vs. 19.9 months; P < .001), and OS

(not reached in the fludarabine arm vs. 69.8 months [95% Cl, 61.6–79.8 months; P = .014] in the chlorambucil arm).<sup>91</sup>

A prospective, multicenter trial evaluated treatment with fludarabine with rituximab in patients with WM (n = 43) who had received less than two prior therapies, of whom 63% had received no prior therapy. The ORR was 95%. The reported median time to progression for all patients was 51.2 months and was longer for untreated patients (P = .017) and those achieving at least a VGPR (P = .049). After a median follow-up of 40.3 months, 3 cases with transformation to aggressive lymphoma and 3 cases with MDS/AML were reported.<sup>92</sup> Fludarabine used alone or in combination with rituximab is listed in the algorithm under Useful in Certain Circumstances for Therapy for Previously Treated WM/LPL.

*Fludarabine/Cyclophosphamide/Rituximab:* A retrospective study of patients with relapsed/refractory WM reported an ORR of 80% after treatment with fludarabine, cyclophosphamide, and rituximab (FCR), 32.5% (n= 13) of patients reaching at least a VGPR.<sup>93</sup> Another multicenter, prospective trial treated previously untreated or pretreated chemotherapy in those with WM (n = 43) with FCR regimen.<sup>94</sup> Most of the participants in this study (65%) received FCR as first-line treatment, 28% of people had relapsed disease, and 7% had disease that was refractory to a previous line of treatment. The results demonstrated that FCR produces rapid response rates of 79%, with high rates of CR and VGPR. There is a risk of PJP associated with FCR treatment, including late onset of PJP.<sup>95</sup> Therefore, the NCCN Panel recommends PJP prophylaxis for those treated with the FCR regimen.

Nucleoside analogs have shown efficacy in relapsed/refractory WM/LPL either alone or in combination with rituximab.<sup>88,92,94</sup> All cladribine- and fludarabine-containing regimens have been listed in the algorithm under Useful in Certain Circumstances for Therapy for Previously Treated WM/LPL.

National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

*Ofatumumab:* Ofatumumab is a human monoclonal antibody (IgG1) that binds specifically to a distinct epitope encompassing both the small and large extracellular loops of the CD20 molecule.<sup>96,97</sup> In cells expressing low levels of CD20, it induces complement-dependent cytotoxicity in vitro that is more potent compared with rituximab.<sup>74,94</sup> Studies demonstrated that ofatumumab could be successfully administered, either as a single agent or as combination therapy with meaningful responses in patients with WM. <sup>98</sup> According to the NCCN Panel ofatumumab may be considered in patients who are intolerant to rituximab, either as single-agent or combination therapy. Therefore, it is listed in the algorithm under Useful in Certain Circumstances for Therapy for Previously Treated WM/LPL.

There is a risk of IgM flare with ofatumumab, as with rituximab. Therefore, similar precautions as with rituximab should be considered when using ofatumumab in those patients who have evidence of hyperviscosity or who have elevated IgM levels.

*RCHOP (rituximab/cyclophosphamide/doxorubicin/vincristine/prednisone):* RCHOP is a stem cell–sparing regimen reported to be active and tolerated by patients with WM.<sup>67,99,100</sup> It has been reported as having at least a 90% response rate in patients with WM.<sup>67,100,101</sup> In a randomized study involving 69 patients, most of whom had WM, the addition of rituximab to CHOP resulted in a higher ORR (94% vs. 67%) and median time to progression (63 vs. 22 months) in comparison to patients treated with CHOP alone.<sup>100</sup> The addition of vincristine to cyclophosphamide-containing regimens is associated with risk of neuropathy in patients with WM.<sup>41</sup> According to the NCCN Panel, since vincristine is associated with a high risk of peripheral neuropathy in patients with WM/LPL, regimens without vincristine (e.g., cyclophosphamide/dexamethasone/rituximab), may be considered if cyclophosphamide-based therapy is being considered.

#### Hematopoietic Cell Transplant (HCT)

HCT is also an option for relapsed WM in selected patients.<sup>102,103</sup> HCT options listed in the NCCN Guidelines for WM/LPL are for high-dose therapy with autologous stem cell rescue.<sup>102,103</sup> According to the NCCN Panel, myeloablative or non-myeloablative allogeneic HCT may be considered,<sup>102</sup> but in the context of a clinical trial.

### **Management of Bing-Neel Syndrome**

Bing-Neel syndrome (BNS) is a rare manifestation of WM which results in the migration of lymphoplasmacytic cells (LPCs) to the central nervous system (CNS).<sup>104,105</sup> Neurological deficits concerning BNS include but are not limited to headaches, seizures, cranial nerve palsies, weakness in limbs, and atypical neuropathy. Differential diagnosis of BNS includes hyperviscosity syndrome (HVS) with CNS manifestation which can present as new-onset of neurological symptoms such as headaches, visual impairment, and nose bleeds.<sup>106</sup> HVS with CNS involvement can be differentiated from BNS by confirming an appropriate increase in serum IgM consistent with levels detected in those with WM, in conjunction with abnormal imaging and/or the presence of clonal B-cells in cerebrospinal fluid (CSF) or cerebral tissue.<sup>107</sup> Diagnostic criteria and workup of BNS includes histology, CSF analysis, molecular testing, radiology, and blood analysis.<sup>106</sup> Neuroimaging is encouraged in order to exclude differential diagnosis and aid in the selection of an appropriate site for biopsy.<sup>106</sup> Two forms of CNS involvement (diffuse and tumoral) can be best evaluated after gadolinium administration and MRI.<sup>106</sup> The diffuse form is associated with infiltration of lymphoid cells in the leptomeningeal sheath and perivascular space. This form presents as an enhancement or thickening of the meningeal sheath. Conversely, the tumoral form can be multifocal or unifocal and is found deep in the subcortical hemisphere.<sup>106</sup> CNS lymphoma histology cannot be detected on an MRI and thus BNS cannot be excluded in the absence of MRI findings. Diagnostic criteria for BNS include histological biopsy of the cerebrum or meninges positive for clonal

National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

B cells with morphological evidence of lymphoplasmacytic lymphoma. Analysis of the CSF should include cell count and differentiation, morphological analysis, flow cytometry, and molecular testing to increase the sensitivity for detecting the presence of malignant B cells in the CSF. Analysis of CSF should be done routinely and should not precede the MRI to eliminate CSF sampling induced meningeal enhancement.<sup>106</sup> Immunoglobulin gene rearrangement assays can also be performed to determine clonal characteristics of a B cell population. In addition, mutations in MYD88 with an amino acid point mutation L265P have been detected in 93-97% of individuals with WM, using highly sensitive diagnostic techniques such as allele-specific PCR.<sup>106</sup> Definitive diagnosis of BNS includes presence of clonal B-cells in CSF or within a tissue biopsy with a typical manifestation and presentation of systemic disease. Diagnosis can be confirmed with or without leptomeningeal enhancement or masses detected with an MRI. A probable diagnosis is made with abnormal MRI findings without evidence of clonal B cells in CSF or tissue biopsy.

If a person has abnormal test results but remains asymptomatic, their treatment will continue with routine observation. If a person is symptomatic, various systemic therapy options are recommended; preferred regimens include BTK inhibitors such as ibrutinib<sup>108</sup> and zanubrutinib. Other recommended regimens include chemotherapy agents such as bendamustine, cytarabine, fludarabine, and methotrexate. Regimens useful in certain circumstances include intrathecal methotrexate and radiotherapy. BNS is a rare and usually a late manifestation in those with WM. It can develop when a person is in remission or less typically at the beginning of disease manifestation.<sup>109</sup> When BNS develops later in the disease, it is usually associated with a worse prognosis.<sup>106,110</sup>

National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

#### References

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110-115. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/12720118">https://www.ncbi.nlm.nih.gov/pubmed/12720118</a>.

2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999;17:3835-3849. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/10577857</u>.

3. Swerdlow S, Campo, E, Harris, NL, et al. WHO Classification of tumours of haematopoietic and lymphoid tissues.: Lyon, France: IARC Press; 2008. p194.

4. Sekhar J, Sanfilippo K, Zhang Q, et al. Waldenstrom macroglobulinemia: a Surveillance, Epidemiology, and End Results database review from 1988 to 2005. Leuk Lymphoma 2012;53:1625-1626. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/22239669</u>.

5. U.S. National Library of Medicine-Key MEDLINE® Indicators. Available at: <u>https://pubmed.ncbi.nlm.nih.gov/about/</u>. Accessed December, 2023.

6. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Vol. 2 (Ed Revised 4th Edition). Geneva: WHO Press: Lyon, France: IARC Press; 2017.

7. Hunter ZR, Branagan AR, Manning R, et al. CD5, CD10, and CD23 expression in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:246-249. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/15794857</u>.

8. Konoplev S, Medeiros LJ, Bueso-Ramos CE, et al. Immunophenotypic profile of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. Am J Clin Pathol 2005;124:414-420. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/16191510</u>.

9. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. N Engl J Med 2012;367:826-833. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/22931316</u>.

10. Castillo JJ, Garcia-Sanz R, Hatjiharissi E, et al. Recommendations for the diagnosis and initial evaluation of patients with Waldenstrom Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstrom Macroglobulinaemia. Br J Haematol 2016;175:77-86. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/27378193</u>.

11. Kyle RA, Treon SP, Alexanian R, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:116-120. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/12720119</u>.

12. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009;113:4163-4170. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/19196866</u>.

13. Paiva B, Montes MC, Garcia-Sanz R, et al. Multiparameter flow cytometry for the identification of the Waldenstrom's clone in IgM-MGUS and Waldenstrom's Macroglobulinemia: new criteria for differential diagnosis and risk stratification. Leukemia 2014;28:166-173. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23604227.

14. Ondrejka SL, Lin JJ, Warden DW, et al. MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders. Am J Clin Pathol 2013;140:387-394. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23955458.

15. Varettoni M, Arcaini L, Zibellini S, et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood 2013;121:2522-2528. Available at:

https://www.ncbi.nlm.nih.gov/pubmed/23355535.

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

16. Treon SP, Xu L, Hunter Z. MYD88 Mutations and Response to Ibrutinib in Waldenstrom's Macroglobulinemia. N Engl J Med 2015;373:584-586. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26244327.

17. Menke MN, Feke GT, McMeel JW, et al. Hyperviscosity-related retinopathy in waldenstrom macroglobulinemia. Arch Ophthalmol 2006;124:1601-1606. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/17102008</u>.

18. Crisp D, Pruzanski W. B-cell neoplasms with homogeneous coldreacting antibodies (cold agglutinins). Am J Med 1982;72:915-922. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/6807086</u>.

19. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2009;114:2375-2385. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19617573.

20. Stone MJ. Waldenstrom's macroglobulinemia: hyperviscosity syndrome and cryoglobulinemia. Clin Lymphoma Myeloma 2009;9:97-99. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/19362986</u>.

21. Garces-Sanchez M, Dyck PJ, Kyle RA, et al. Antibodies to myelinassociated glycoprotein (anti-Mag) in IgM amyloidosis may influence expression of neuropathy in rare patients. Muscle Nerve 2008;37:490-495. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/18236455</u>.

22. Levine T, Pestronk A, Florence J, et al. Peripheral neuropathies in Waldenstrom's macroglobulinaemia. J Neurol Neurosurg Psychiatry 2006;77:224-228. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/16421127">https://www.ncbi.nlm.nih.gov/pubmed/16421127</a>.

23. D'Sa S, Kersten MJ, Castillo JJ, et al. Investigation and management of IgM and Waldenstrom-associated peripheral neuropathies: recommendations from the IWWM-8 consensus panel. Br J Haematol 2017;176:728-742. Available at:

https://www.ncbi.nlm.nih.gov/pubmed/28198999.

24. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016;66:443-459. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/27618563</u>.

25. Kastritis E, Kyrtsonis MC, Morel P, et al. Competing risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapy. Haematologica 2015;100:e446-449. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/26294729">https://www.ncbi.nlm.nih.gov/pubmed/26294729</a>.

26. Bustoros M, Sklavenitis-Pistofidis R, Kapoor P, et al. Progression Risk Stratification of Asymptomatic Waldenstrom Macroglobulinemia. J Clin Oncol 2019;37:1403-1411. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30990729.

27. Castillo JJ, Olszewski AJ, Cronin AM, et al. Survival trends in Waldenstrom macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results database. Blood 2014;123:3999-4000. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/24948623</u>.

28. Kyle RA, Benson JT, Larson DR, et al. Progression in smoldering Waldenstrom macroglobulinemia: long-term results. Blood 2012;119:4462-4466. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/22451426</u>.

29. Kyle RA, Larson DR, Therneau TM, et al. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance. N Engl J Med 2018;378:241-249. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29342381.

30. Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019;30:860-862. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30520968.

31. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenstrom Macroglobulinaemia. Lancet Haematol 2020;7:e827-e837. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/33091356">https://www.ncbi.nlm.nih.gov/pubmed/33091356</a>.

NCCN National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

32. Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenstrom macroglobulinaemia-A British Society for Haematology guideline. Br J Haematol 2022;197:171-187. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/35020191">https://www.ncbi.nlm.nih.gov/pubmed/35020191</a>.

33. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher 2016;31:149-162. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/27322218</u>.

34. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenstrom macroglobulinemia treated with nucleoside analogs. J Clin Oncol 2009;27:250-255. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19064987.

35. Dimopoulos MA, Zervas C, Zomas A, et al. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma 2002;3:163-166. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/12521393">https://www.ncbi.nlm.nih.gov/pubmed/12521393</a>.

36. Rummel MJ, von Gruenhagen U, Niederle N, et al. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with Waldenstrom's macroglobulinemia: first interim results of a randomized phase III study of the Studygroup Indolent Lymphomas (StiL) [abstract]. Proceedings of the 5th International Workshop on Waldenstrom's macroglobulinemia; Stockholm, Sweden 2008;Abstract 139. Available at: http://www.ncbi.nlm.nih.gov/pubmed/19362960.

37. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013;381:1203-1210. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/23433739</u>.

38. Greil R, Wupperfeld J, Hinke A, et al. Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial). Blood 2019;134:343-343. Available at:

https://www.sciencedirect.com/science/article/pii/S0006497118582616.

39. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570-1575. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17353550.

40. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom Macroglobulinemia. Am J Hematol 2010;85:670-674. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/20652865</u>.

41. Treon SP, loakimidis L, Soumerai JD, et al. Primary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol 2009;27:3830-3835. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/19506160</u>.

42. Chen C, Kouroukis CT, White D, et al. Bortezomib in relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:74-76. Available at: https://www.ncbi.nlm.nih.gov/pubmed/19362979.

43. Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood 2013;122:3276-3282. Available at: https://www.ncbi.nlm.nih.gov/pubmed/24004667.

44. Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013;31:88-94. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/23045577</u>.

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

45. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenstrom's macroglobulinemia. N Engl J Med 2015;372:1430-1440. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/25853747</u>.

46. Treon SP, Meid K, Gustine J, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia. J Clin Oncol 2021;39:565-575. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/32931398</u>.

47. Castillo JJ, Meid K, Gustine JN, et al. Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia. Leukemia 2022;36:532-539. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/34531537">https://www.ncbi.nlm.nih.gov/pubmed/34531537</a>.

48. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia. N Engl J Med 2018;378:2399-2410. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29856685.

49. Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Treatment in Waldenström's Macroglobulinemia: Follow-up Efficacy and Safety from the iNNOVATETM Study. Blood 2018;132:149-149. Available at: <u>https://doi.org/10.1182/blood-2018-99-111178</u>.

50. Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenstrom's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol 2022;40:52-62. Available at:

https://www.ncbi.nlm.nih.gov/pubmed/34606378.

51. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study. Blood 2020;136:2038-2050. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/32731259">https://www.ncbi.nlm.nih.gov/pubmed/32731259</a>.

52. Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib Versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: Final Analysis From the Randomized Phase III ASPEN Study. J Clin Oncol 2023:JCO2202830. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/37478390</u>.

53. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:133-135. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/21454214">https://www.ncbi.nlm.nih.gov/pubmed/21454214</a>.

54. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom's macroglobulinemia. Blood 2014;124:503-510. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/24859363</u>.

55. Meid K, Dubeau T, Severns P, et al. Long-Term Follow-up of a Prospective Clinical Trial of Carfilzomib, Rituximab and Dexamethasone (CaRD) in Waldenstrom's Macroglobulinemia. Blood 2017;130:2772-2772. Available at:

https://www.sciencedirect.com/science/article/pii/S0006497119832883.

56. Castillo JJ, Meid K, Gustine JN, et al. Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstrom Macroglobulinemia. Clin Cancer Res 2018;24:3247-3252. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/29661775</u>.

57. Castillo JJ, Meid K, Flynn CA, et al. Ixazomib, dexamethasone, and rituximab in treatment-naive patients with Waldenstrom macroglobulinemia: long-term follow-up. Blood Adv 2020;4:3952-3959. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/32822482</u>.

58. Gertz MA, Rue M, Blood E, et al. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047-2055. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/15370249</u>.

59. Treon SP, Emmanouilides C, Kimby E, et al. Extended rituximab therapy in Waldenstrom's macroglobulinemia. Ann Oncol 2005;16:132-138. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/15598950</u>.

60. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study.

National Comprehensive Cancer Network®

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

Cancer 2004;101:2593-2598. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15493038.

61. Treon SP, Branagan AR, Hunter Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004;15:1481-1483. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/15367407">https://www.ncbi.nlm.nih.gov/pubmed/15367407</a>.

62. Treon SP. How I treat Waldenstrom macroglobulinemia. Blood 2015;126:721-732. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/26002963</u>.

63. Zivkovic SA. Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Rev Neurother 2006;6:1267-1274. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/17009914">https://www.ncbi.nlm.nih.gov/pubmed/17009914</a>.

64. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344-3349. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/17577016</u>.

65. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 study. Blood 2015;126:1392-1394. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26359434.

66. Paludo J, Abeykoon JP, Kumar S, et al. Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemia. Br J Haematol 2017;179:98-105. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28786474.

67. loakimidis L, Patterson CJ, Hunter ZR, et al. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:62-66. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/19362976">https://www.ncbi.nlm.nih.gov/pubmed/19362976</a>.

68. Treon SP, Hanzis C, Manning RJ, et al. Maintenance Rituximab is associated with improved clinical outcome in rituximab naive patients with Waldenstrom Macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol 2011;154:357-362. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/21615385">https://www.ncbi.nlm.nih.gov/pubmed/21615385</a>.

69. Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstrom macroglobulinaemia. Br J Haematol 2018;181:77-85. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/29468652</u>.

70. Treon SP, Tedeschi A, San-Miguel J, et al. Report of consensus Panel 4 from the 11th International Workshop on Waldenstrom's macroglobulinemia on diagnostic and response criteria. Semin Hematol 2023;60:97-106. Available at: https://www.ncbi.nlm.nih.gov/pubmed/37173155.

71. Treon SP, Hunter ZR, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007;13:3320-3325. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/17545538</u>.

72. Strauss SJ, Maharaj L, Hoare S, et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006;24:2105-2112. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16606971.

73. Varghese AM, Rawstron AC, Ashcroft AJ, et al. Assessment of bone marrow response in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:53-55. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/19362973</u>.

74. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016. JAMA Oncol 2017;3:1257-1265. Available at: https://www.ncbi.nlm.nih.gov/pubmed/28056114.

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

75. Tedeschi A, Picardi P, Ferrero S, et al. Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemia. Leuk Lymphoma 2015;56:2637-2642. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/25651423</u>.

76. Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol 2018;97:1417-1425. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29610969.

77. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005;90:1655-1658. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/16330439">https://www.ncbi.nlm.nih.gov/pubmed/16330439</a>.

78. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422-1428. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/20142586</u>.

79. Agathocleous A, Rohatiner A, Rule S, et al. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010;151:346-353. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/20880120</u>.

80. Jagannath S, Richardson PG, Barlogie B, et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-934. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/16818280</u>.

81. Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenstrom macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol 2020;7:e112-e121. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/31866281">https://www.ncbi.nlm.nih.gov/pubmed/31866281</a>.

82. Kersten MJ, Amaador K, Minnema MC, et al. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study. J Clin Oncol 2022;40:40-51. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/34388022</u>.

83. Dimopoulos MA, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab. J Clin Oncol 2002;20:2327-2333. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/11981004</u>.

84. Cao Y, Yang G, Hunter ZR, et al. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol 2015;170:134-138. Available at: https://www.ncbi.nlm.nih.gov/pubmed/25582069.

85. Castillo JJ, Allan JN, Siddiqi T, et al. Venetoclax in Previously Treated Waldenstrom Macroglobulinemia. J Clin Oncol 2022;40:63-71. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/34793256</u>.

86. Dimopoulos MA, Kantarjian H, Estey E, et al. Treatment of Waldenstrom macroglobulinemia with 2-chlorodeoxyadenosine. Ann Intern Med 1993;118:195-198. Available at: https://www.ncbi.nlm.nih.gov/pubmed/8093333.

87. Weber DM, Dimopoulos MA, Delasalle K, et al. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003;30:243-247. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/12720145</u>.

88. Laszlo D, Andreola G, Rigacci L, et al. Rituximab and subcutaneous 2chloro-2'-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010;28:2233-2238. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/20368573</u>.

89. Ghobrial IM, Gertz MA, LaPlant B, et al. A phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

waldenstrom's macroglobulinemia [abstract]. Blood 2009;114:Abstract 587. Available at:

http://abstracts.hematologylibrary.org/cgi/content/abstract/114/22/587.

90. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol 2014;89:237-242. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/24716234</u>.

91. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenstrom macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol 2013;31:301-307. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/23233721">https://www.ncbi.nlm.nih.gov/pubmed/23233721</a>.

92. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113:3673-3678. Available at: https://www.pcbi.plm.pib.gov/pubmed/19015393

https://www.ncbi.nlm.nih.gov/pubmed/19015393.

93. Tedeschi A, Ricci F, Goldaniga MC, et al. Fludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2013;13:231-234. Available at:

94. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012;118:434-443. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/21732338</u>.

95. Haeusler GM, Slavin MA, Seymour JF, et al. Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis. Eur J Haematol 2013;91:157-163. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/23668894</u>.

96. Teeling JL, Mackus WJ, Wiegman LJ, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

J Immunol 2006;177:362-371. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16785532.

97. Pawluczkowycz AW, Beurskens FJ, Beum PV, et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183:749-758. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/19535640</u>.

98. Furman RR, Eradat HA, DiRienzo CG, et al. Once-weekly ofatumumab in untreated or relapsed Waldenstrom's macroglobulinaemia: an openlabel, single-arm, phase 2 study. Lancet Haematol 2017;4:e24-e34. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/27914971</u>.

99. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005;5:273-277. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/15794864</u>.

100. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23:153-161. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/18818699">https://www.ncbi.nlm.nih.gov/pubmed/18818699</a>.

101. Abonour R, Zhang LA, Rajkumar V, et al. Phase II pilot study of rituximab + CHOP in patients with newly diagnosed Waldenstrom's macroglobulinemia, an Eastren Cooperative Oncology Group Trial (Study E1A02) [abstract]. Blood 2007;110:Asbtract 3616. Available at: http://abstracts.hematologylibrary.org/cgi/content/abstract/110/11/3616.

102. Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28:4926-4934. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/20956626</u>.

NCCN National Comprehensive Cancer Network<sup>®</sup>

### NCCN Guidelines Version 1.2025 Waldenström Macroglobulinemia/ Lymphoplasmacytic Lymphoma

ISSI

103. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28:2227-2232. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/20368570</u>.

104. Kotsos D, Chatzileontiadou S, Apsemidou A, et al. Bing-Neel Syndrome: Real-Life Experience in Personalized Diagnostic Approach and Treatment. Front Oncol 2022;12:891052. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/35847958</u>.

105. Ravi G, Kapoor P. Current approach to Waldenstrom Macroglobulinemia. Cancer Treat Res Commun 2022;31:100527. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/35149375</u>.

106. Minnema MC, Kimby E, D'Sa S, et al. Guideline for the diagnosis, treatment and response criteria for Bing-Neel syndrome. Haematologica 2017;102:43-51. Available at: <a href="https://www.ncbi.nlm.nih.gov/pubmed/27758817">https://www.ncbi.nlm.nih.gov/pubmed/27758817</a>.

107. Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012;119:2205-2208. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/22147890</u>.

108. Castillo JJ, Itchaki G, Paludo J, et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood 2019;133:299-305.

109. Castillo JJ, D'Sa S, Lunn MP, et al. Central nervous system involvement by Waldenstrom macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study. Br J Haematol 2016;172:709-715. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/26686858</u>.

110. Simon L, Fitsiori A, Lemal R, et al. Bing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO). Haematologica 2015;100:1587-1594. Available at: <u>https://www.ncbi.nlm.nih.gov/pubmed/26385211</u>.